DK3452513T3 - Humaniserede anti-il-ir3-antistoffer - Google Patents

Humaniserede anti-il-ir3-antistoffer Download PDF

Info

Publication number: DK3452513T3
Authority: DK; Denmark
Prior art keywords: antibodies; humanized anti; humanized
Prior art date: 2016-05-06

Application number

DK17724778.0T

Other languages

English (en)

Inventor

Stephan Fischer

Michael Brandt

Linda Veronique Kazandjian

Original Assignee

Sanofi Biotechnology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-06

Filing date

2017-05-08

Publication date

2024-07-15

2017-05-08 Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology

2024-07-15 Application granted granted Critical

2024-07-15 Publication of DK3452513T3 publication Critical patent/DK3452513T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK17724778.0T 2016-05-06 2017-05-08 Humaniserede anti-il-ir3-antistoffer DK3452513T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16168617.5A EP3241845A1 (en)	2016-05-06	2016-05-06	Humanized anti-il-1r3 antibodies
PCT/EP2017/060925 WO2017191325A1 (en)	2016-05-06	2017-05-08	Humanized anti-il-1r3 antibodies

Publications (1)

Publication Number	Publication Date
DK3452513T3 true DK3452513T3 (da)	2024-07-15

Family

ID=55919721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17724778.0T DK3452513T3 (da)	2016-05-06	2017-05-08	Humaniserede anti-il-ir3-antistoffer

Country Status (24)

Country	Link
US (3)	US11203642B2 (da)
EP (3)	EP3241845A1 (da)
JP (3)	JP7038462B2 (da)
KR (3)	KR102550643B1 (da)
CN (3)	CN116178549A (da)
AU (2)	AU2017260399B2 (da)
CA (1)	CA3022657A1 (da)
DK (1)	DK3452513T3 (da)
EA (1)	EA201892541A1 (da)
ES (1)	ES2982075T3 (da)
FI (1)	FI3452513T3 (da)
HR (1)	HRP20240961T1 (da)
HU (1)	HUE066965T2 (da)
IL (2)	IL262776B2 (da)
LT (1)	LT3452513T (da)
MX (2)	MX2018013517A (da)
NZ (1)	NZ748130A (da)
PL (1)	PL3452513T3 (da)
PT (1)	PT3452513T (da)
RS (1)	RS65804B1 (da)
SG (1)	SG11201809764XA (da)
SI (1)	SI3452513T1 (da)
WO (1)	WO2017191325A1 (da)
ZA (1)	ZA201807167B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108026172B (zh)	2015-06-26	2022-04-29	赛诺菲生物技术公司	单克隆抗il-1racp抗体
EP3241845A1 (en)	2016-05-06	2017-11-08	MAB Discovery GmbH	Humanized anti-il-1r3 antibodies
EP3592384B1 (en) *	2017-03-09	2025-07-02	MAB Discovery GmbH	Antibodies specifically binding to human il-1r7
EP3401332A1 (en)	2017-05-08	2018-11-14	MAB Discovery GmbH	Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018231827A1 (en)	2017-06-12	2018-12-20	Bluefin Biomedicine, Inc.	Anti-il1rap antibodies and antibody drug conjugates
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
PE20231575A1 (es)	2020-09-14	2023-10-04	Ichnos Sciences SA	Anticuerpos que se unen a il1rap y usos de estos
EP4288457A2 (en) *	2021-02-05	2023-12-13	Boehringer Ingelheim International GmbH	Anti-il1rap antibodies
MX2023013714A (es)	2021-05-21	2024-01-16	Leo Pharma As	Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1).
CN117642431B (zh) *	2021-07-13	2025-07-15	迈威(美国)生物治疗有限公司	抗c1s抗体和其用途
US12054552B2 (en)	2022-09-21	2024-08-06	Sanofi Biotechnology	Humanized anti-IL-1R3 antibody and methods of use
CN116574189A (zh) *	2023-01-30	2023-08-11	北京智仁美博生物科技有限公司	针对人il-36r和/或人il-1r3的多种抗体及其用途
CN116284401B (zh) *	2023-02-20	2024-09-24	中国人民解放军军事科学院军事医学研究院	人源抗il-1r3抗体及其应用
AU2024397535A1 (en) *	2023-12-13	2026-07-02	Systimmune, Inc.	Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof
WO2026022232A1 (en)	2024-07-24	2026-01-29	Almirall, S.A.	Il-1rap inhibitor for treating or preventing hidradenitis suppurativa

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5283179A (en)	1990-09-10	1994-02-01	Promega Corporation	Luciferase assay method
DE69126281T2 (de)	1990-11-26	1997-10-16	Akzo Nobel Nv	Verfahren zur Herstellung von Antikörpern
PE64396A1 (es)	1995-01-23	1997-01-28	Hoffmann La Roche	Proteina accesoria del receptor de la interleucina 1
US6974682B1 (en)	1996-08-26	2005-12-13	Human Genome Sciences, Inc.	Soluble interleukin-1 receptor accessory molecule
EP0915987A2 (en)	1997-04-21	1999-05-19	Donlar Corporation	POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6280955B1 (en)	1997-12-16	2001-08-28	Tularik Inc.	Interleukin-1 receptor accessory proteins, nucleic acids and methods
JP4334141B2 (ja)	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6541225B1 (en)	2000-01-26	2003-04-01	Raven Biotechnologies, Inc.	Methods and compositions for generating human monoclonal antibodies
US7449443B2 (en)	2000-03-23	2008-11-11	California Institute Of Technology	Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en)	2000-05-26	2003-07-01	California Institute Of Technology	Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20030026806A1 (en)	2000-10-27	2003-02-06	Amgen Inc.	Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7049095B2 (en)	2000-10-31	2006-05-23	Immunex Corporation	DNA encoding IL-1 receptor accessory protein
US20030049255A1 (en)	2001-08-07	2003-03-13	Sims John E.	Interleukin-1 receptors in the treatment of diseases
EP1490677A4 (en)	2002-02-27	2006-01-18	California Inst Of Techn	COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
MXPA05002514A (es)	2002-09-06	2005-05-27	Amgen Inc	Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
KR101498588B1 (ko)	2003-01-22	2015-03-05	로슈 글리카트 아게	융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US20040224893A1 (en)	2003-05-06	2004-11-11	Li-Hsien Wang	Methods of using IL-1 antagonists to treat neointimal hyperplasia
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
EP1675620B1 (en)	2003-10-09	2019-05-08	Ambrx, Inc.	Polymer derivatives
HUE038955T2 (hu)	2003-11-05	2018-12-28	Roche Glycart Ag	Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JP2007522118A (ja) *	2004-01-30	2007-08-09	ペプリンバイオリピッズピーティーワイエルティーディー	治療用分子および担体分子
BRPI0507169A (pt)	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EP2343363A1 (en)	2005-07-01	2011-07-13	John Schrader	Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining
AU2006290433B2 (en)	2005-08-26	2012-06-07	Roche Glycart Ag	Modified antigen binding molecules with altered cell signaling activity
EP2021463B1 (en)	2006-05-19	2016-11-23	Alder Biopharmaceuticals, Inc.	Culture method for obtaining a clonal population of antigen-specific b cells
WO2009120905A2 (en)	2008-03-26	2009-10-01	Cellerant Therapeutics, Inc.	Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
KR20150036824A (ko)	2009-03-20	2015-04-07	제넨테크, 인크.	이중특이적 항-ｈｅｒ 항체
GB2472856B (en)	2009-08-21	2012-07-11	Cantargia Ab	IL1-RAP modulators and uses thereof
KR20130070576A (ko) *	2010-04-09	2013-06-27	노보자임스 바이오파마 디케이 에이/에스	알부민 유도체 및 변이체
SI2400298T1 (sl)	2010-05-28	2013-11-29	F. Hoffmann-La Roche Ag	Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
JP5940093B2 (ja)	2011-01-19	2016-06-29	カンタージアアクチエボラーグ	抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
LT2691417T (lt)	2011-03-29	2018-10-25	Roche Glycart Ag	Antikūno fc variantai
WO2012142391A1 (en)	2011-04-15	2012-10-18	Merck Patemt Gmbh	Anti- il-1r1 inhibitors for use in cancer
JP2014527398A (ja) *	2011-06-21	2014-10-16	オンコファクターコーポレイション	がんの療法および診断のための組成物および方法
US9873918B2 (en)	2011-08-11	2018-01-23	Albert Einstein College Of Medicine, Inc.	Treatment of acute myeloid leukemia and myelodysplastic syndromes
US9212227B2 (en)	2012-04-30	2015-12-15	Janssen Biotech, Inc.	ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
US20150315279A1 (en) *	2012-12-21	2015-11-05	Cellerant Therapeutics, Inc.	Antibodies that bind membrane-bound il1rap
WO2014113433A1 (en)	2013-01-16	2014-07-24	George Mason University	Binding domain mapping
GB201403875D0 (en) *	2014-03-05	2014-04-16	Cantargia Ab	Novel antibodies and uses thereof
US20150315179A1 (en)	2014-05-02	2015-11-05	Torrey Pines Institute For Molecular Studies	Compounds and methods of treating neurological disorders
GB201413913D0 (en) *	2014-08-06	2014-09-17	Cantargia Ab	Novel antibodies and uses thereof
CN108026172B (zh)	2015-06-26	2022-04-29	赛诺菲生物技术公司	单克隆抗il-1racp抗体
EP3241845A1 (en)	2016-05-06	2017-11-08	MAB Discovery GmbH	Humanized anti-il-1r3 antibodies
EP3401332A1 (en)	2017-05-08	2018-11-14	MAB Discovery GmbH	Anti-il-1r3 antibodies for use in inflammatory conditions

2016
- 2016-05-06 EP EP16168617.5A patent/EP3241845A1/en not_active Withdrawn
2017
- 2017-05-08 EA EA201892541A patent/EA201892541A1/ru unknown
- 2017-05-08 AU AU2017260399A patent/AU2017260399B2/en active Active
- 2017-05-08 DK DK17724778.0T patent/DK3452513T3/da active
- 2017-05-08 KR KR1020227010275A patent/KR102550643B1/ko active Active
- 2017-05-08 RS RS20240776A patent/RS65804B1/sr unknown
- 2017-05-08 KR KR1020237021882A patent/KR20230107695A/ko not_active Ceased
- 2017-05-08 US US16/099,059 patent/US11203642B2/en active Active
- 2017-05-08 PT PT177247780T patent/PT3452513T/pt unknown
- 2017-05-08 HR HRP20240961TT patent/HRP20240961T1/hr unknown
- 2017-05-08 MX MX2018013517A patent/MX2018013517A/es unknown
- 2017-05-08 CN CN202211533431.5A patent/CN116178549A/zh active Pending
- 2017-05-08 CN CN201780041725.7A patent/CN109415442B/zh active Active
- 2017-05-08 PL PL17724778.0T patent/PL3452513T3/pl unknown
- 2017-05-08 CA CA3022657A patent/CA3022657A1/en active Pending
- 2017-05-08 SI SI201731536T patent/SI3452513T1/sl unknown
- 2017-05-08 ES ES17724778T patent/ES2982075T3/es active Active
- 2017-05-08 EP EP24169816.6A patent/EP4434540A3/en active Pending
- 2017-05-08 HU HUE17724778A patent/HUE066965T2/hu unknown
- 2017-05-08 EP EP17724778.0A patent/EP3452513B1/en active Active
- 2017-05-08 WO PCT/EP2017/060925 patent/WO2017191325A1/en not_active Ceased
- 2017-05-08 CN CN202211533197.6A patent/CN116178548A/zh active Pending
- 2017-05-08 SG SG11201809764XA patent/SG11201809764XA/en unknown
- 2017-05-08 IL IL262776A patent/IL262776B2/en unknown
- 2017-05-08 LT LTEPPCT/EP2017/060925T patent/LT3452513T/lt unknown
- 2017-05-08 KR KR1020187034930A patent/KR102381257B1/ko active Active
- 2017-05-08 JP JP2019510473A patent/JP7038462B2/ja active Active
- 2017-05-08 NZ NZ748130A patent/NZ748130A/en unknown
- 2017-05-08 FI FIEP17724778.0T patent/FI3452513T3/fi active
2018
- 2018-10-26 ZA ZA2018/07167A patent/ZA201807167B/en unknown
- 2018-11-05 MX MX2023002554A patent/MX2023002554A/es unknown
2021
- 2021-08-24 US US17/410,153 patent/US12024564B2/en active Active
2022
- 2022-03-03 JP JP2022032317A patent/JP7480199B2/ja active Active
- 2022-10-23 IL IL297527A patent/IL297527B2/en unknown
2024
- 2024-04-23 JP JP2024069425A patent/JP2024102134A/ja active Pending
- 2024-05-20 US US18/668,446 patent/US20240409644A1/en active Pending
- 2024-06-13 AU AU2024204004A patent/AU2024204004A1/en active Pending

Also Published As

Publication number	Publication date
KR20230107695A (ko)	2023-07-17
EP3452513B1 (en)	2024-04-17
PT3452513T (pt)	2024-07-09
SI3452513T1 (sl)	2024-10-30
PL3452513T3 (pl)	2024-09-16
KR102550643B1 (ko)	2023-07-03
KR102381257B1 (ko)	2022-04-04
US11203642B2 (en)	2021-12-21
CN109415442B (zh)	2022-12-23
IL297527B2 (en)	2026-08-01
ES2982075T3 (es)	2024-10-14
CN109415442A (zh)	2019-03-01
IL297527A (en)	2022-12-01
HRP20240961T1 (hr)	2024-10-25
JP2024102134A (ja)	2024-07-30
RS65804B1 (sr)	2024-08-30
MX2018013517A (es)	2019-07-08
FI3452513T3 (fi)	2024-07-05
CA3022657A1 (en)	2017-11-09
EP4434540A3 (en)	2024-12-25
SG11201809764XA (en)	2018-12-28
IL262776B2 (en)	2023-03-01
EP3241845A1 (en)	2017-11-08
JP7480199B2 (ja)	2024-05-09
US20190194336A1 (en)	2019-06-27
KR20220042499A (ko)	2022-04-05
AU2024204004A1 (en)	2024-08-01
JP7038462B2 (ja)	2022-03-18
AU2017260399B2 (en)	2024-03-14
US20240409644A1 (en)	2024-12-12
LT3452513T (lt)	2024-08-12
BR112018072681A2 (pt)	2019-02-19
JP2019516787A (ja)	2019-06-20
HUE066965T2 (hu)	2024-09-28
IL262776A (en)	2018-12-31
WO2017191325A9 (en)	2018-01-04
EA201892541A1 (ru)	2019-03-29
NZ748130A (en)	2022-08-26
BR112018072681A8 (pt)	2023-04-11
CN116178549A (zh)	2023-05-30
CN116178548A (zh)	2023-05-30
JP2022078191A (ja)	2022-05-24
MX2023002554A (es)	2023-04-10
WO2017191325A1 (en)	2017-11-09
IL262776B (en)	2022-11-01
IL297527B1 (en)	2026-04-01
ZA201807167B (en)	2019-06-26
US12024564B2 (en)	2024-07-02
EP3452513A1 (en)	2019-03-13
NZ788000A (en)	2025-06-27
US20220089751A1 (en)	2022-03-24
KR20190004762A (ko)	2019-01-14
AU2017260399A1 (en)	2018-11-29
EP4434540A2 (en)	2024-09-25

Publication	Publication Date	Title
CY2025001I2 (el)	2026-02-25	Νεα αντι-pd-l1 αντισωματα
IL272227A (en)	2020-03-31	Anti-tigit antibodies
IL269405A (en)	2019-11-28	Anti-sirp alpha antibodies
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
EP3661558A4 (en)	2021-08-11	ANTI-IL1RAP ANTIBODIES
PT3606954T (pt)	2022-09-16	Anticorpos anti-lag3
EP3532489A4 (en)	2020-07-08	ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
EP3569709A4 (en)	2020-08-19	ANTI-GPC3 ANTIBODIES
DK3455257T3 (da)	2021-11-01	Anti-pd-l1-antistoffer
EP3481869A4 (en)	2020-02-26	ANTI-CD73 ANTIBODIES
HUE051700T2 (hu)	2021-03-29	Anti-PD-1 antitestek
KR20180085002A (ko)	2018-07-25	인간화된 항-cll-1 항체
EP3387442A4 (en)	2019-05-08	HUMANIZED ANTI-CD73 ANTIBODIES
EP3691447A4 (en)	2021-08-11	ANTI-TRANSTHYRETINE ANTIBODY
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
LT3452513T (lt)	2024-08-12	Humanizuoti anti-il-1r3 antikūnai
EP3182987C0 (en)	2023-09-27	HUMANIZED ANTI-TAU ANTIBODIES
IL256097A (en)	2018-02-28	Antibody epitope
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
DK3350218T3 (da)	2024-04-02	Polyomavirus-neutraliserende antistoffer
DK3250593T3 (da)	2022-08-22	Anti-transthyretin-antistoffer
IL248402B (en)	2020-10-29	Humanized antibodies against ceacam1
HUE061076T2 (hu)	2023-05-28	Humanizált anti-C1s ellenanyagok alkalmazási eljárások
DK3116908T3 (da)	2019-10-07	Humaniserede kir3dl2-antistoffer
PL3474904T3 (pl)	2024-12-16	Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb